Key Drivers
- Margin durability
- Weak cash conversion
- Tight liquidity
AIAI Summary
STVN should now be viewed less as a steady packaging compounder and more as a higher-value platform story, with the key investment test being whether rising high-value mix, Alina®/Deora™ momentum, and 26% EBITDA margins can translate into durable free cash flow once capex normalizes—because at ~32x earnings, any cash-conversion slip leaves little room for error.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin durability
- •Weak cash conversion
- •Tight liquidity
STVN stayed solidly profitable with strong 2025 margins and manageable leverage, but softer quarterly margins, negative free cash flow, thinning liquidity, and a rich valuation make execution and cash conversion the key risks.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout held
- •Near-term hesitation
Over the last month, STVN has trended higher with repeated higher lows and support building around $20.0-$20.6, but it remains extended and still needs a decisive break above $21.5-$21.6 to confirm the breakout.
Small pullback after the $21.52 peak suggests near-term hesitation
Sentiment & News
Key News Insights:
- •Revenue growth
- •Margin improvement
- •EU approvals
Stevanato Group posted 8% Q2 revenue growth, beat EPS estimates, and benefited from stronger high-value product demand and new European approvals, though its outlook was adjusted for the Balda divestiture.
The update is mildly bullish for Stevanato Group, as operational momentum and product validation appear to outweigh the near-term guidance change
Similar Companies in Healthcare
Other companies in the same sector with AI ratings